骨髓移植市场－全球产业规模、份额、趋势、机会、预测：按类型、治疗类型、地区和竞争格局划分，2021-2031年

全球骨髓移植市场预计将从 2025 年的 129.9 亿美元成长到 2031 年的 172.8 亿美元，复合年增长率为 4.87%。

造血干细胞移植，也称为造血干细胞移植，是一种复杂的治疗手术，透过用健康的干细胞取代受损的骨髓来治疗淋巴瘤、白血病和骨髓瘤等恶性肿瘤。市场成长的主要驱动力是血液癌症发生率的上升以及单倍体相合移植技术的进步，后者使得非同胞供者也能获得完全匹配的捐赠者。全球扩大供体库的努力也促进了这一成长。世界骨髓捐赠者协会（WMDA）报告称，到2024年，其国际登记处已登记了超过4400万名志愿者捐赠者和脐带血製品，这大大提高了不同患者匹配成功的可能性。

然而，该市场面临一个重大障碍：手术及长期管理费用高昂。这些经济负担包括移植前预处理、手术本身以及移植物抗宿主疾病等併发症的长期照护。这种经济负担限制了移植服务的可近性，尤其是在医疗基础设施不发达或报销体係不完善的地区。

市场驱动因素

骨髓恶性肿瘤发生率的上升是推动市场成长的主要动力，造血干细胞移植（HSCT）作为根治性白血病、骨髓瘤和淋巴瘤等疾病的必要治疗方法，其重要性日益凸显。不断加重的癌症负担推动了全球对移植手术的持续需求。美国癌症协会于2025年1月发布的《2025年癌症事实与数据》报告也印证了这一趋势，该报告预测，仅当年美国就将新增66,890例白血病病例和89,070例淋巴瘤病例，凸显了这些治疗方法在控制危及生命的血液系统疾病方面的重要性。

此外，造血干细胞移植（HSCT）技术的进步，特别是单倍体相合通讯协定的进步，透过缓解捐赠者短缺问题，正在扩大市场。移植物抗宿主疾病（GVHD）预防方面的创新，例如移植后使用Cyclophosphamide，已使部分相合的亲缘供体成为标准选择，从而减少了对完全相合的非亲缘供体的需求。国际血液和骨髓移植中心（CIBMT）在2025年8月报告称，2023年单倍体相合供体占所有异基因移植的21%。这一适应症的扩大也反映在移植数量的成长上。根据欧洲血液和骨髓移植协会2025年2月的报告，2023年共进行了47,731例移植手术，比前一年增加了7.8%。

市场挑战

骨髓移植及其后续治疗的高昂费用是市场成长的主要障碍。这一经济障碍源于手术的复杂性、严格的移植前准备以及必要的长期术后监测。因此，许多医疗保险不足或居住在医疗预算有限的地区的患者无法获得这些救命治疗，从而缩小了潜在市场规模。此外，建造专业设施需要大量资金投入，这意味着服务主要集中在富裕地区，医疗基础设施落后地区的人们无法获得足够的医疗服务。

移植手术带来的经济负担因治疗移植物抗宿主疾病等併发症的费用而进一步加重，这些併发症涉及昂贵的药物以及再次入院的可能性。根据美国血液学会统计，2024年移植手术期间每位病患的医疗费用中位数约为331,827美元。这些高昂的费用往往导致保险公司拒付率居高不下，患者需要承担巨额自付费用，造成经济摩擦，这限制了每年的手术数量，儘管临床需求不断增长。

市场趋势

基因编辑造血干细胞疗法的兴起代表着该行业的模式转移，它为无需依赖匹配供体的遗传性血液疾病提供了根治性疗法。这一趋势涉及将自体干细胞在体外进行基因修饰，从而消除移植物抗宿主疾病的风险，并扩大其适用患者群体。近期财务数据表明，这种方法具有市场可行性。 2025年11月，Vertex Pharmaceuticals在第三季财报中报告称，其基因编辑疗法Casgevy已创造1,700万美元的收入，凸显了这些先进基因介入疗法的快速普及和立竿见影的效果。

同时，将人工智慧（AI）整合到供体配型中，透过改进人类白血球抗原（HLA）的选择和风险评估，正在革新移植前的流程。先进的机器学习演算法现在被用于解读复杂的生物学数据，使临床医生比传统方法更准确地预测移植结果和併发症。这种向数据驱动型改进的转变正在推动医疗保健水准的提升。 2025年3月，RPH报告称，其客製化的AI模型在预测干细胞移植存活率方面达到了89%的准确率，这表明该领域正朝着个人化医疗的方向迈出重要一步。

目录

第一章概述

第二章：调查方法

第三章执行摘要

第四章：客户心声

第五章：全球骨髓移植市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 按类型（自体移植、异体移植、其他）
  • 依类型治疗（白血病、淋巴瘤、骨髓瘤、骨髓发育不良症候群、骨髓增殖性疾病、再生障碍性贫血、固态肿瘤、镰状细胞贫血、地中海贫血、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美骨髓移植市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国别分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲骨髓移植市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国别分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区骨髓移植市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国别分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲骨髓移植市场展望

• 市场规模及预测
• 市占率及预测
• 中东与非洲：国别分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲骨髓移植市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国别分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 促进因素
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 近期趋势

第十三章：全球骨髓移植市场：SWOT分析

第十四章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的议价能力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• Merck KGaA
• SANOFI WINTHROP INDUSTRIE
• AllCells, LLC
• STEMCELL Technologies Canada Inc.
• American Type Culture Collection
• Charles River Laboratories International, Inc.
• Fujifilm Cellular Dynamics, Inc.
• ReachBio LLC
• PromoCell GmbH
• Mesoblast Ltd

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Bone Marrow Transplant Market is projected to expand from USD 12.99 Billion in 2025 to USD 17.28 Billion by 2031, reflecting a compound annual growth rate of 4.87%. Also termed hematopoietic stem cell transplantation, this complex procedure replaces damaged marrow with healthy stem cells to treat malignancies like lymphoma, leukemia, and myeloma. Market momentum is largely driven by the increasing incidence of blood cancers and technological breakthroughs in haploidentical transplantation, which allow for donors beyond fully matched siblings. Global efforts to boost donor pools further support this growth; the World Marrow Donor Association noted in 2024 that the international registry included over 44 million volunteer donors and cord blood products, significantly improving match probabilities for diverse patients.

However, the market faces a substantial hurdle in the form of high costs related to the procedure and long-term management. The financial strain encompasses pre-transplant conditioning, the surgery itself, and extended care for complications such as graft-versus-host disease. This economic burden restricts access, especially in areas with developing healthcare infrastructure or insufficient reimbursement systems.

Market Driver

The rising incidence of hematologic malignancies stands as the primary engine for market growth, with conditions like leukemia, myeloma, and lymphoma often requiring hematopoietic stem cell transplantation (HSCT) as a curative measure. This growing cancer burden drives a continuous demand for transplant procedures globally. Highlighting this trend, the American Cancer Society's "Cancer Facts & Figures 2025" report from January 2025 projected 66,890 new leukemia diagnoses and 89,070 lymphoma cases in the United States for that year alone, emphasizing the critical reliance on these therapies for managing life-threatening blood disorders.

Furthermore, technological refinements in HSCT, specifically regarding haploidentical protocols, have widened the market by mitigating donor shortages. Innovations in graft-versus-host disease (GVHD) prophylaxis, such as post-transplant cyclophosphamide, have established partially matched family donors as a standard option, lessening the need for fully matched unrelated donors. The Center for International Blood and Marrow Transplant Research reported in August 2025 that haploidentical related donors comprised 21% of all allogeneic transplants in 2023. This broadened eligibility is reflected in procedure volumes; the European Society for Blood and Marrow Transplantation's February 2025 report noted 47,731 transplants in 2023, marking a 7.8% rise in allogeneic activity from the previous year.

Market Challenge

The substantial expenses linked to bone marrow transplantation and ongoing care serve as a major impediment to market growth. This financial barrier stems from the intricate nature of the procedure, rigorous pre-transplant conditioning, and necessary long-term post-operative monitoring. Consequently, patients without adequate insurance and healthcare systems operating on restricted budgets are often unable to access these life-saving therapies, reducing the potential market size. Additionally, the high capital investment required for specialized facilities limits availability primarily to affluent regions, leaving populations in developing healthcare infrastructures underserved.

The economic pressure is intensified by the cost of managing complications such as graft-versus-host disease, which requires expensive medication and potential hospital readmissions. According to the American Society of Hematology, the median healthcare cost per patient during the transplant period alone was approximately $331,827 in 2024. These prohibitive costs frequently result in high claim denial rates by payers or substantial out-of-pocket burdens for patients, creating economic friction that restricts the annual volume of procedures despite increasing clinical demand.

Market Trends

The rise of gene-edited hematopoietic stem cell therapies marks a paradigm shift in the industry, offering curative treatments for genetic blood disorders that do not rely on matched donors. This trend involves the commercialization of autologous stem cells modified ex vivo to rectify genetic errors, thereby eliminating graft-versus-host disease risks and expanding patient eligibility. The market viability of this approach is evident in recent financial data; in November 2025, Vertex Pharmaceuticals reported in its third-quarter results that its gene-edited therapy, Casgevy, achieved $17 million in revenue, highlighting the rapid adoption and immediate impact of these advanced genetic interventions.

Simultaneously, the integration of artificial intelligence into donor matching is revolutionizing the pre-transplant process by improving human leukocyte antigen (HLA) selection and risk assessment. Advanced machine learning algorithms are now utilized to interpret complex biological data, enabling clinicians to forecast transplant outcomes and complications with greater accuracy than traditional methods. This shift toward data-driven precision is enhancing care standards; GlobalRPH reported in March 2025 that custom AI models recently attained an 89% precision rate in predicting stem cell transplant survival, signaling a distinct evolution toward personalized medicine within the sector.

Key Market Players

• Merck KGaA
• SANOFI WINTHROP INDUSTRIE
• AllCells, LLC
• STEMCELL Technologies Canada Inc.
• American Type Culture Collection
• Charles River Laboratories International, Inc.
• Fujifilm Cellular Dynamics, Inc.
• ReachBio LLC
• PromoCell GmbH
• Mesoblast Ltd

Report Scope

In this report, the Global Bone Marrow Transplant Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bone Marrow Transplant Market, By Type

• Autologous Transplant
• Allogenic Transplant
• Others

Bone Marrow Transplant Market, By Treatment Type

• Leukemia
• Lymphoma
• Myeloma
• Myelodysplastic Syndrome
• Myeloproliferative Disorders
• Aplastic Anemia
• Solid Tumors
• Sickle cell Anemia
• Thalassemia
• Others

Bone Marrow Transplant Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Bone Marrow Transplant Market.

Available Customizations:

Global Bone Marrow Transplant Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bone Marrow Transplant Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Autologous Transplant, Allogenic Transplant, Others)
  • 5.2.2. By Treatment Type (Leukemia, Lymphoma, Myeloma, Myelodysplastic Syndrome, Myeloproliferative Disorders, Aplastic Anemia, Solid Tumors, Sickle cell Anemia, Thalassemia, Others)
  • 5.2.3. By Region
  • 5.2.4. By Company (2025)
• 5.3. Market Map

6. North America Bone Marrow Transplant Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Treatment Type
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bone Marrow Transplant Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Treatment Type
  • 6.3.2. Canada Bone Marrow Transplant Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Treatment Type
  • 6.3.3. Mexico Bone Marrow Transplant Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Treatment Type

7. Europe Bone Marrow Transplant Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Treatment Type
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bone Marrow Transplant Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Treatment Type
  • 7.3.2. France Bone Marrow Transplant Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Treatment Type
  • 7.3.3. United Kingdom Bone Marrow Transplant Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Treatment Type
  • 7.3.4. Italy Bone Marrow Transplant Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Treatment Type
  • 7.3.5. Spain Bone Marrow Transplant Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Treatment Type

8. Asia Pacific Bone Marrow Transplant Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Treatment Type
  • 8.2.3. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Bone Marrow Transplant Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Treatment Type
  • 8.3.2. India Bone Marrow Transplant Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Treatment Type
  • 8.3.3. Japan Bone Marrow Transplant Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Treatment Type
  • 8.3.4. South Korea Bone Marrow Transplant Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Treatment Type
  • 8.3.5. Australia Bone Marrow Transplant Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Treatment Type

9. Middle East & Africa Bone Marrow Transplant Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Treatment Type
  • 9.2.3. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Bone Marrow Transplant Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Treatment Type
  • 9.3.2. UAE Bone Marrow Transplant Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Treatment Type
  • 9.3.3. South Africa Bone Marrow Transplant Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Treatment Type

10. South America Bone Marrow Transplant Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Treatment Type
  • 10.2.3. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Bone Marrow Transplant Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Treatment Type
  • 10.3.2. Colombia Bone Marrow Transplant Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Treatment Type
  • 10.3.3. Argentina Bone Marrow Transplant Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Treatment Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Bone Marrow Transplant Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Merck KGaA
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. SANOFI WINTHROP INDUSTRIE
• 15.3. AllCells, LLC
• 15.4. STEMCELL Technologies Canada Inc.
• 15.5. American Type Culture Collection
• 15.6. Charles River Laboratories International, Inc.
• 15.7. Fujifilm Cellular Dynamics, Inc.
• 15.8. ReachBio LLC
• 15.9. PromoCell GmbH
• 15.10. Mesoblast Ltd

16. Strategic Recommendations

17. About Us & Disclaimer